Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody

As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Mono...

Full description

Saved in:
Bibliographic Details
Published in:Science translational medicine 2017-04, Vol.9 (384), p.eaai8711-eaai8711
Main Authors: Mire, Chad E, Geisbert, Joan B, Borisevich, Viktoriya, Fenton, Karla A, Agans, Krystle N, Flyak, Andrew I, Deer, Daniel J, Steinkellner, Herta, Bohorov, Ognian, Bohorova, Natasha, Goodman, Charles, Hiatt, Andrew, Kim, Do H, Pauly, Michael H, Velasco, Jesus, Whaley, Kevin J, Crowe, Jr, James E, Zeitlin, Larry, Geisbert, Thomas W
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - therapeutic use
Cross Protection
Ebolavirus
Filoviridae - physiology
Filoviridae Infections - drug therapy
Filoviridae Infections - virology
Filovirus
Guinea Pigs
Humans
Macaca fascicularis
Macaca mulatta
Marburg Virus Disease - drug therapy
Marburg Virus Disease - virology
Marburgvirus
Marburgvirus - physiology
Pilot Projects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.
ISSN:1946-6234
1946-6242
DOI:10.1126/scitranslmed.aai8711